Pseudolaric acid B exhibits anti-cancer activity on human hepatocellular carcinoma through inhibition of multiple carcinogenic signaling pathways
Authors:
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 59, 152759
Abstract
No abstract availableKeywords
Funding Information
- Health and Family Planning Commission of Sichuan Province (17PJ485)
- Discipline Talent Promotion Program of "Xinglin Scholars” (QNXZ2018005)
This publication has 41 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Pseudolaric acids: isolation, bioactivity and synthetic studiesNatural Product Reports, 2010
- Convergence between Wnt-β-catenin and EGFR signaling in cancerMolecular Cancer, 2010
- Emerging roles of E2Fs in cancer: an exit from cell cycle controlNature Reviews Cancer, 2009
- Mitochondrial STAT3 Supports Ras-Dependent Oncogenic TransformationScience, 2009
- Apoptosis in cancer: Key molecular signaling pathways and therapy targetsActa Oncologica, 2009
- Protein tyrosine kinase, JNK, and ERK involvement in pseudolaric acid B-induced apoptosis of human breast cancer MCF-7 cells1Acta Pharmacologica Sinica, 2008
- Pseudolaric Acid B, a Novel Microtubule-Destabilizing Agent That Circumvents Multidrug Resistance Phenotype and Exhibits Antitumor Activity In vivoClinical Cancer Research, 2005
- Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-CateninMolecular Cell, 2005
- Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinomaJournal of Surgical Oncology, 2003